Emergency care is now in a state of emergency as missed targets reach an all-time high, bed occupancy rates surge, and flu cases increase sharply, and health chiefs warn that patients are “dying in corridors” and the system is “on
read moreRoche’s Ocrevus has been approved for use in Europe to treat adults with relapsing multiple sclerosis (RMS) and early primary progressive multiple sclerosis (PPMS). More: EU clears Roche’s Ocrevus for MS Source: News
read moreEli Lilly has steered away from megadeals, and a big influx of cash from U.S. tax reform won’t change that. Darren Carroll, SVP of business development, thinks behemoth buys will get the biggest boost as companies bring overseas earnings home,
read moreOut of several potential buyers for Merck KGaA’s consumer health unit, one bidder has risen to the top: Nestle, which has its sights set on a bigger role in healthcare. More: Nestle takes the lead over Mylan, Reckitt in Merck
read moreNovartis brought on Pfizer executive Liz Barrett to head up its oncology outfit after Bruno Strigini’s retirement. One of her signature accomplishments: The rollout of Ibrance, a breast cancer drug among Pfizer’s biggest recent successes—and a head-to-head competitor to Novartis’
read moreWith plans for further expansion in China, Japan’s Eisai has opened a new solid dose plant there which will be able to produce 3 billion tablets a year. More: Eisai completes solid dose plant in Suzhou, China Source: fierce
read more© 1994 - 2024 B.M. Pharmaceuticals